Modality
ADC
MOA
MDM2i
Target
IL-13
Pathway
Incretin
CholangiocarcinomaNASHHS
Development Pipeline
Preclinical
~Feb 2017
→ ~May 2018
Phase 1
Aug 2018
→ Sep 2030
Phase 1Current
NCT08871647
2,120 pts·NASH
2018-08→TBD·Not yet recruiting
NCT06168115
1,687 pts·NASH
2022-04→2030-09·Terminated
3,807 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-09-054.4y awayInterim· NASH
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P1
Not yet…
P1
Termina…
Catalysts
Interim
2030-09-05 · 4.4y away
NASH
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08871647 | Phase 1 | NASH | Not yet recr... | 2120 | UPDRS |
| NCT06168115 | Phase 1 | NASH | Terminated | 1687 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| MRN-7601 | Moderna | Phase 2 | IL-13 | |
| Capiglumide | BioNTech | Preclinical | CGRP |